[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-liver-disease-cld\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-liver-disease-cld":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,77,109,140,163,180,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644494","phase-4-vitamin-d2-versus-vitamin-d2-plus-calcitriol-in-cholestatic-children-with-vitamin-d-deficiency-100644494",false,"NCT07670611","VITAMIN D2 VERSUS VITAMIN D2 PLUS CALCITRIOL IN CHOLESTATIC CHILDREN WITH VITAMIN D DEFICIENCY","ACCELERATED CORRECTION OF VITAMIN D DEFICIENCY IN CHOLESTATIC CHILDREN: A COMPARATIVE TRIAL OF VITAMIN D2 MONOTHERAPY VERSUS COMBINATION THERAPY WITH CALCITRIOL","VITD-CHOL","Inclusion Criteria:\n\n* Patients younger than 18 years of age.\n* Patients diagnosed with cholestasis, defined as direct\u002Fconjugated bilirubin \\>1 mg\u002FdL for more than 1 month.\n* Patients diagnosed with chronic liver disease.\n* Patients with vitamin D deficiency, defined as serum 25-hydroxyvitamin D (25-OHD) level \\\u003C20 ng\u002FmL, according to the Endocrine Society Clinical Practice Guideline.\n\nExclusion Criteria:\n\n* Pre-existing hypercalciuria, screened by urine calcium testing before enrollment.\n* Patients with benign or malignant tumors.\n* Patients with renal tubular defects, screened by electrolyte testing before enrollment.\n* Patients currently receiving anticonvulsant therapy.\n* Patients who do not attend scheduled follow-up visits.","ALL","18 Years",{"count":20,"type":21},54,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn whether adding calcitriol to vitamin D2 can improve vitamin D deficiency in children with cholestasis and chronic liver disease. Cholestasis is a condition in which bile flow is reduced, which can make it difficult for the body to absorb and process vitamin D. The study will also learn about the safety of using vitamin D2 together with calcitriol.\n\nThe main questions it aims to answer are:\n\n* Does vitamin D2 plus calcitriol increase blood 25-hydroxyvitamin D (25-OHD) levels more than vitamin D2 alone after 3 months of treatment?\n* Does vitamin D2 plus calcitriol help more children reach an adequate vitamin D level by 3 and 6 months?\n* What medical problems, especially high calcium or high phosphorus levels, occur during treatment?\n\nResearchers will compare children who receive vitamin D2 alone with children who receive vitamin D2 plus calcitriol to see which treatment improves vitamin D levels more effectively and safely.\n\nParticipants will:\n\n* Take vitamin D2 alone or vitamin D2 plus calcitriol as assigned by randomization\n* Visit the clinic for study assessments at the start of the study, at 3 months, and at 6 months\n* Have blood tests to measure vitamin D levels, calcium, phosphorus, parathyroid hormone, liver function, and other safety markers\n* Have their treatment reviewed at 3 months; participants whose vitamin D level remains low may have their treatment adjusted according to the study plan\n* Bring back medication packages so researchers can check how regularly the study medicines were taken",[27,28,29,30],"Cholestatic Liver Disease","Chronic Liver Disease (CLD)","Vitamin D Deficiency","Children",[32,33,34,35,36],"cholestasis","pediatrics","vitamin d deficiency","Calcitriol","25-Hydroxyvitamin D2","RECRUITING","2026-06-22",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":43,"type":41},"2026-04-28",{"date":45,"type":21},"2027-04-20",{"name":47,"class":48},"Chulalongkorn University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100638873","phase-1-a-clinical-trial-to-assess-the-pharmacokinetics-safety-and-food-effect-of-ad-230-in-healthy-adults-100638873","NCT07618845","A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults","A Randomized, Open-label, 2-period, 2-sequence, Crossover Study to Evaluate the Food Effect on the Safety and the Pharmacokinetics of AD-230 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"19 Years","64 Years",{"count":61,"type":21},24,[63],"PHASE1","A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults",[28],"NOT_YET_RECRUITING","2026-05-26",{"date":69,"type":41},"2026-06-01",{"date":71,"type":21},"2026-05",{"date":73,"type":21},"2026-07",{"name":75,"class":76},"Addpharma Inc.","INDUSTRY",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":88,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":49},"100639234","correlation-of-eus-swq-and-liver-fibrosis-pathology-in-chronic-liver-disease-100639234","NCT07588854","Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease","EU-ME3 Endoscopic Ultrasound Shear Wave Quantification (EUS-SWQ) for Evaluating Liver Fibrosis and Histopathology in Patients With Chronic Liver Disease","EUS-SWQ-202601","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 80 years.\n2. Patients with clinical indications scheduled to undergo liver biopsy (EUS-guided) for the evaluation of liver lesions. Chronic liver disease meeting criteria for biopsy includes:Hepatitis B；Fatty liver disease；Autoimmune hepatitis；Other chronic liver diseases of unknown etiology that would benefit from liver biopsy\n3. Planned to undergo EUS-SWQ and FibroScan examinations prior to biopsy.\n4. Willing to provide and sign written informed consent.\n\nExclusion Criteria:\n\n1. Patients unable to tolerate endoscopic procedures.\n2. Patients with contraindications to endoscopy or anesthesia.\n3. Coagulopathy (platelet count \\\u003C 50×10⁹\u002FL, PT \\> upper limit of normal by 3 seconds).\n4. Patients with severe underlying diseases of the respiratory, cardiovascular, cerebrovascular, digestive, or hematologic systems, as well as those with psychiatric disorders.\n5. Patients with surgically altered anatomy that precludes adequate EUS imaging of the hepatic parenchyma.\n6. Patients with imaging findings suggestive of malignant liver tumors.\n7. Pregnant or lactating women.\n8. Patients with decompensated cirrhosis (gastrointestinal bleeding, ascites, encephalopathy).\n9. Patients who refuse to participate in the clinical study.\n10. Any other conditions deemed inappropriate by the investigator.","80 Years",{"count":87,"type":21},65,"2 Weeks","OBSERVATIONAL","The goal of this clinical study is to learn whether the Olympus EU-ME3 endoscopic ultrasound shear wave quantification (EUS-SWQ) function can accurately diagnose and grade liver fibrosis in patients with chronic liver disease. It will also learn about the safety and measurement success rate of EUS-SWQ.\n\nThe main questions it aims to answer are:\n\nHow closely do EUS-SWQ measurements match liver fibrosis stages determined by liver biopsy (the reference standard)? Does EUS-SWQ correlate better with liver biopsy results than FibroScan? How safe is EUS-SWQ and how often can successful measurements be obtained? Researchers will compare EUS-SWQ results with liver biopsy pathology (METAVIR F0-F4) and with FibroScan results to evaluate its diagnostic value.\n\nParticipants will:\n\nBe adults with chronic liver disease who are scheduled to undergo a clinically indicated liver biopsy Undergo an EUS-SWQ examination as part of the study Have their liver stiffness measured by both EUS-SWQ and FibroScan for comparison Be monitored for any discomfort or adverse events related to the procedures A total of 65 participants will take part in this prospective, single-center, post-market clinical study.",[28,92],"Liver Fibrosis",[94,95,96,97,98,99,100],"Chronic liver disease","Liver fibrosis","EUS-SWQ","Endoscopic ultrasound","Liver biopsy","FibroScan","Olympus EU-ME3","2026-05-13",{"date":103,"type":41},"2026-05-15",{"date":71,"type":21},{"date":106,"type":21},"2028-01",{"name":108,"class":48},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":118,"conditions":119,"keywords":126,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100636914","ultrasound-prediction-of-esophageal-variceal-bleeding-risk-100636914","NCT07571876","Ultrasound Prediction of Esophageal Variceal Bleeding Risk","Splenic Size and Portal Vein Diameter on Ultrasound in Predicting Esophageal Variceal Bleeding Risk","Inclusion Criteria:\n\n* Adult patients (age ≥18 years) with chronic liver disease and clinical\u002Flaboratory\u002Fradiological evidence of liver cirrhosis\n* Both compensated and decompensated cirrhosis (Child-Pugh classes A, B, and C)\n* Patients scheduled for upper gastrointestinal endoscopy\n* Patients who provide informed consent\n\nExclusion Criteria:\n\n* Previous history of endoscopic variceal band ligation or sclerotherapy\n* Prior surgical portosystemic shunt procedures or transjugular intrahepatic portosystemic shunt (TIPS)\n* Hepatocellular carcinoma with portal vein thrombosis\n* Previous splenectomy\n* Patients receiving beta-blockers for variceal bleeding prophylaxis\n* Poor quality ultrasound images due to obesity or ascites\n* Refusal to participate in the study",{"count":117,"type":21},165,"This prospective observational study aims to evaluate the accuracy of using routine abdominal ultrasound to predict the risk of esophageal variceal bleeding in adult patients with liver cirrhosis. Esophageal variceal bleeding is a serious complication of chronic liver disease. While upper gastrointestinal endoscopy is the current standard for diagnosing and grading these varices, it is an invasive procedure.\n\nIn this study, researchers will use ultrasound to measure the patient's spleen size and portal vein diameter. These non-invasive measurements will then be compared to the results of a standard upper endoscopy performed within 48 to 72 hours. The goal is to determine if these simple ultrasound measurements can reliably predict the presence, grade, and bleeding risk of esophageal varices, which could potentially reduce the need for routine invasive endoscopic screenings in the future.",[120,121,122,123,124,125,28],"Variceal Bleeding","Ultrasonography","Esophageal Bleeding","Esophageal Varices","Liver Cirrhosis","Portal Hypertension",[127,128,129,130],"portal vein diameter","splenic size","ultrasound","esophageal variceal bleeding risk","2026-05-04",{"date":133,"type":41},"2026-05-06",{"date":135,"type":21},"2026-04",{"date":137,"type":21},"2027-05",{"name":139,"class":48},"Assiut University",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":161,"locationsCount":49},"100620601","assessing-signatures-for-fibrosis-detection-in-chronic-liver-disease-a-step-beyond-conventional-biomarkers-100620601","NCT07359742","Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers","Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers.","Inclusion Criteria:\n\n* ≥18y\n* Chronic liver disease: alcohol, metabolic dysfunction associated steatotic liver disease, viral hepatitis, autoimmune hepatitis, cholestatic liver disease and hemochromatosis\n\nExclusion Criteria:\n\n* \\\u003C18y\n* Acute hepatitis\n* Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.",{"count":148,"type":21},110,[150],"NA","Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development. When hepatocytes are damaged, HSCs undergo myofibroblast differentiation, transitioning into an activated state. So far, no efficient biomarkers can estimate the degree of HSC activation or reversal across all aetiologies of CLD, although this could be a more sensitive marker than fibrosis measurement which is secondary to HSC activation. This study aims to correlate biomarkers to the fibrosis stage in a larger cohort of patients with CLD across all aetiologies.",[28,153],"Fibrosis of Liver",[155,156],"chronic liver disease","fibrosis","2026-04-30",{"date":133,"type":41},{"date":71,"type":21},{"date":106,"type":21},{"name":162,"class":48},"Universitair Ziekenhuis Brussel",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":167,"conditions":173,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":178,"leadSponsor":179,"locationsCount":49},"100633019","phase-1-a-clinical-trial-to-evaluate-the-pharmacokinetics-and-safety-of-ad-230-in-healthy-adults-100633019","NCT07521241","A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults","A Randomized, Open-label, Two-treatment, Two-period, Two-sequence Crossover Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults","Inclusion Criteria:\n\n* \\- Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":171,"type":21},52,[63],[28],"2026-04-08",{"date":176,"type":41},"2026-04-13",{"date":71,"type":21},{"date":73,"type":21},{"name":75,"class":76},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":204,"locationsCount":4},"100631554","heart-problems-in-children-with-chronic-liver-disease-100631554","NCT07502196","Heart Problems in Children With Chronic Liver Disease","Assessment of Cardiac Problems in Children With Chronic Liver Disease","Inclusion Criteria:\n\n* All patients below 18 years who diagnosed with chronic liver disease.\n\nExclusion Criteria:\n\n* All patients known to have congenital heart disease or previous cardiac disease.","17 Years",{"count":189,"type":21},60,"Chronic liver disease (CLD) in children can sometimes lead to complications in other parts of the body, including the heart. The primary purpose of this observational study is to assess the presence and type of cardiac problems in children who have been diagnosed with chronic liver disease.\n\nResearchers will observe children under the age of 18 who are receiving care at the gastroenterology and hepatology unit at Assiut University Children Hospital. Participants will undergo standard medical evaluations to check both their liver and heart health.\n\nThese evaluations include:\n\n* A detailed medical history and thorough physical examination\n* Routine blood tests to check liver function, kidney function, coagulation, and electrolytes\n* Abdominal imaging, such as an ultrasound, to look at the liver.\n* An electrocardiogram (ECG) to check the heart's electrical activity and rhythm, including measuring the QTc interval.\n* An echocardiogram to look at the structure of the heart and check how well its chambers and valves are functioning.\n\nThe study aims to identify specific heart conditions that can be associated with severe liver disease, such as portopulmonary hypertension, cirrhotic cardiomyopathy (changes in the heart muscle's function), and electrical repolarization abnormalities. Children who already have known congenital heart disease or a history of other heart problems will not be included in the study.",[28,124,192,193,194],"Cardiac Abnormalities","Portopulmonary Hypertension","Cirrhotic Cardiomyopathy",[196,124,197,193,194,198],"Chronic Liver Disease","Cardiac Problems","Cardiac Repolarization Abnormalities","2026-03-25",{"date":201,"type":41},"2026-03-30",{"date":135,"type":21},{"date":137,"type":21},{"name":139,"class":48},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":49},"100582415","eus-guided-portal-pressure-gradient-ppg-measurement-a-potential-alternative-to-the-traditional-hvpg-100582415","NCT06863012","EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG","EUS-PPG","Inclusion Criteria:\n\n* Subjects must be 18 to 85 years of age inclusive, at the time of signing the informed consent form.\n* Subjects who have a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement.\n* Subjects capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Significant bleeding risk (International Normalized Ratio (INR) \\> 1.5 OR platelet count \\\u003C 50000).\n* Presence of active gastrointestinal bleeding at the time of screening\n* History of any blood thinner consumption (e.g. warfarin, heparin, novel roal anticoagulants) within the last 5 days.\n* Presence of massive ascites causing abdominal distension or requiring frequent therapeutic paracentesis.\n* Subjects having received previous Transjugular Intrahepatic Portosystemic Shunt (TIPS) or Surgical Portosystemic Shunt.\n* Hepatocellular carcinoma not meeting Milan Criteria.\n* Presence of portal vein thrombosis or another suspected component of presinusoidal portal hypertension.\n* Presence of extra-hepatic cancer, terminal disease, or severe comorbidities significantly limiting life expectancy or affecting study participation.\n* Stenosis or surgical anatomical alterations of the gastrointestinal tract that could preclude endoscopic access with the echoendoscope.","85 Years",{"count":214,"type":21},20,[150],"The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative to the traditional hepatic venous pressure gradient (HVPG) method in patients with portal hypertension due to chronic liver disease. The main questions it aims to answer are:\n\n* What is the correlation between EUS-PPG and HVPG measurements in patients with portal hypertension due to cirrhosis?\n* Can EUS-PPG serve as a reliable and less invasive alternative to HVPG for assessing portal pressure?\n* What are the safety outcomes associated with EUS-PPG compared to HVPG?\n\nResearchers will compare EUS-PPG measurements with HVPG measurements within the same patients to assess whether EUS-PPG provides accurate and clinically comparable portal pressure readings while reducing procedural risks.\n\nParticipants will:\n\n* Be adults aged 18 to 85 with a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement.\n* Undergo both EUS-PPG and HVPG measurements within a seven-day window to allow for direct comparison of results.\n* Receive standard clinical care for their condition, including routine diagnostic evaluations and portal hypertension management as needed.\n* Be monitored for safety outcomes, including adverse events such as bleeding, infection, perforation, and any other complications related to the procedure.\n* Provide relevant demographic and clinical data, including liver disease history, Child-Pugh and MELD scores, and portal hypertension-related complications such as varices or ascites.",[125,28,218],"Cirrhosis",[220,221,222,223],"Hepatic Venous Pressure Gradient","Endoscopic Ultrasound-Guided Portal Pressure Gradient","Portal hypertension","Non-Invasive Diagnostic Methods for Portal Hypertension","2025-08-11",{"date":226,"type":41},"2025-08-12",{"date":228,"type":41},"2025-04-16",{"date":230,"type":21},"2025-12",{"name":232,"class":48},"Fundacio Privada Mon Clinic Barcelona"]